Mikhail Blagosklonny is Spreading Awareness of the Practice of Oncology

An established professor of oncology at the Roswell Park Cancer Institute, Mikhail Blagosklonny’s studies lie primarily in the realm of cancer and aging. He earned an MD in internal medicine at the Medical University of St. Petersburg, where he also earned a Ph.D. in Experimental Medicine and Cardiology. In the New York Medical College, located in Valhalla, New York, Blagosklonny was appointed the associate professor of medicine. This opened doors for him to transfer from the college to serve as the senior scientist at the Ordway Research Institute and eventually he joined the Roswell Park Cancer Institute in the position of Professor of Oncology, as recent as 2009.

His experience is apparent in the handful of roles he’s worked in and has gained invaluable knowledge along his journey, which he now brings to the table in order to enrich the education of his students at the Ordway Research Institute. At the heart of his interests for research is Biogerontology, which is the study of the underlying details behind aging. The professor also teaches and actively researches in subjects including cancer, anti-aging drugs, and in methods that target cancer cells in order to prevent healthy cells from being affected. So, in essence, cancer prevention methods and medicines.

View: https://scholar.google.com/citations?user=REO9YogAAAAJ&hl=en

Aside from his role as Professor of Oncology, Mikhail Blagosklonny also holds a position as the editor-in-chief of Oncotarget and Cell Cycle and as such, serves also as the associate editor of cancer biology and therapy. Among his many positions as an oncology professional, he has also received the esteemed position on the editorial board for Cell Death and Differentiation. During his extensive studies, Mikhail has a strong belief in the drug Rapamycin, which is a popular drug used in treating cancer. He hypothesizes that it is a possible solution for use in life extension and has been deemed one of the more passionate oncologists in support of the drug Rapamycin. He has dedicated much of his time in researching the drug and its benefits in longevity treatment.

Mikhail Blagosklonny’s research into Rapamycin ranges from molecular biology studies to cellular to clinical investigations. It includes in large part tumor suppressors, ontogenesis, signal transduction, apoptosis, anticancer therapeutics, mitosis, cell cycle, and normal cells selective protection. As such, Mikhail is an avid writer on these subjects and writs about these topics, as well as other topics that interest him, such as aging hyperfunction theory, chemotherapeutic engineering, and cell cyclotherapy. Visit classroomvoices.org to read more about Mikhail.